Simulations Plus, Inc. (NASDAQ:SLP) Shares Purchased by Ameriprise Financial Inc.

Ameriprise Financial Inc. boosted its holdings in Simulations Plus, Inc. (NASDAQ:SLP - Free Report) by 16.7% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 607,902 shares of the technology company's stock after purchasing an additional 86,868 shares during the quarter. Ameriprise Financial Inc. owned about 3.03% of Simulations Plus worth $16,954,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Jones Financial Companies Lllp lifted its holdings in shares of Simulations Plus by 53.6% in the 4th quarter. Jones Financial Companies Lllp now owns 1,223 shares of the technology company's stock valued at $34,000 after purchasing an additional 427 shares during the last quarter. Johnson Financial Group Inc. purchased a new stake in shares of Simulations Plus in the 4th quarter valued at about $39,000. Tower Research Capital LLC TRC lifted its holdings in shares of Simulations Plus by 42.2% in the 4th quarter. Tower Research Capital LLC TRC now owns 2,575 shares of the technology company's stock valued at $72,000 after purchasing an additional 764 shares during the last quarter. AlphaQuest LLC lifted its holdings in shares of Simulations Plus by 502.9% in the 4th quarter. AlphaQuest LLC now owns 2,689 shares of the technology company's stock valued at $75,000 after purchasing an additional 2,243 shares during the last quarter. Finally, KLP Kapitalforvaltning AS purchased a new stake in shares of Simulations Plus in the 4th quarter valued at about $86,000. 78.08% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Simulations Plus

In other Simulations Plus news, Director Walter S. Woltosz sold 20,000 shares of the stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $33.51, for a total value of $670,200.00. Following the completion of the transaction, the director now owns 3,344,157 shares in the company, valued at approximately $112,062,701.07. This represents a 0.59% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 19.40% of the company's stock.

Simulations Plus Price Performance

Shares of SLP stock traded down $0.20 during midday trading on Monday, hitting $31.33. The company had a trading volume of 146,713 shares, compared to its average volume of 211,826. The company's 50 day simple moving average is $29.06 and its 200 day simple moving average is $30.28. Simulations Plus, Inc. has a 52-week low of $23.01 and a 52-week high of $50.98. The stock has a market cap of $630.08 million, a price-to-earnings ratio of 78.33 and a beta of 1.10.

Simulations Plus (NASDAQ:SLP - Get Free Report) last announced its earnings results on Thursday, April 3rd. The technology company reported $0.31 earnings per share for the quarter, beating the consensus estimate of $0.25 by $0.06. Simulations Plus had a return on equity of 6.84% and a net margin of 10.97%. The company had revenue of $22.43 million for the quarter, compared to the consensus estimate of $21.93 million. During the same period last year, the business posted $0.20 EPS. The company's revenue was up 22.5% on a year-over-year basis. Analysts anticipate that Simulations Plus, Inc. will post 1.09 EPS for the current year.

Analyst Upgrades and Downgrades

SLP has been the subject of a number of recent research reports. StockNews.com upgraded shares of Simulations Plus from a "sell" rating to a "hold" rating in a research note on Monday, April 28th. KeyCorp increased their price target on shares of Simulations Plus from $32.00 to $40.00 and gave the stock an "overweight" rating in a research note on Wednesday, April 16th. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $50.00.

Simulations Plus Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.